Patent US5424286A successfully refreshed from Google Patents.
US5424286A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Assignee: Individual
•
Filing: 1993-05-24
•
Granted: 1995-06-13
•
Expires: 2013-05-24
Abstract
Abstract This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
Inventors
- 👤 John Eng
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:10
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57563; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
13 words
A polypeptide having the amino acid sequence: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG P[SEQ ID No:3].
Claim 2
Dependent Claim
13 words
A polypeptide having the amino acid sequence: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG P[SEQ ID No:3].
Claim 3
Dependent Claim
13 words
A polypeptide having the amino acid sequence: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG Y[SEQ ID No:4].
Claim 4
Dependent Claim
13 words
A polypeptide having the amino acid sequence: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG Y[SEQ ID No:4].
Claim 5
Dependent Claim
41 words
A pharmaceutical composition which comprises an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence of claim 1 in a suitable carrier, which will stimulate the secretion of insulin in vivo.
Claim 6
Dependent Claim
41 words
A pharmaceutical composition which comprises an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified form natural sources, having the amino acid sequence of claim 2 in a suitable carrier, which will stimulate the secretion of insulin in vivo.
Claim 7
Independent Claim
53 words
A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence: HSDGTFITSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 1), wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.
Claim 8
Independent Claim
53 words
A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence: HSDGTFITSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 1), wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.
Claim 9
Independent Claim
53 words
A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 2), wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.
Claim 10
Independent Claim
53 words
A method of stimulating insulin release in a mammal comprising administering an effective insulinotropic amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence: HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 2), wherein the resulting insulinotropic effect is greater than that attainable by administration of GLP-1.
Claim 11
Independent Claim
38 words
A method of inhibiting insulin release in a mammal comprising administering an effective amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence: DL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 5).
Claim 12
Independent Claim
38 words
A method of inhibiting insulin release in a mammal comprising administering an effective amount of a substantially pure polypeptide, synthetic or purified from natural sources, having the amino acid sequence: DL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 5).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-12 | 1998-12-12 | 1999-06-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-12 | 2002-12-12 | 2003-06-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-12 | 2006-12-12 | 2007-06-13 | $7700.00 | Window Closed / Lapsed |